Entering text into the input field will update the search result below

Enanta falls 21% as fiscal 2023 Q2 revenue misses

May 08, 2023 5:48 PM ETEnanta Pharmaceuticals, Inc. (ENTA)By: Jonathan Block, SA News Editor
Quarterly results

CharlieAJA

  • Enanta Pharmaceuticals (NASDAQ:ENTA) is down 21% in after-hours trading after its fiscal 2023 Q2 results missed on the top line.
  • Revenue of $17.8M was a ~5% year-over-year decline. Consensus was $19.06M.
  • Enanta's (ENTA) net loss widened 12% to $37.7M compared to the year-ago period (-$1.79 per share diluted vs -$1.63).
  • The company was negatively impacted in the quarter by a ~9% increase in operating expenses to ~$57.2M.
  • Enanta (ENTA) ended the quarter with cash and cash equivalents of $73.2M, a ~6% increase compared to September 30, 2022.

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.